The big talk in Washington, DC, currently is around rebate reform, as it is called, which could represent one of the biggest policy changes to impact US drug manufacturers since the implementation of Medicare Part D. Right now, there is a lot of uncertainty about which policies might ultimately be implemented, but a wide range of options appear to be under consideration.
Eliminating rebates altogether would represent an enormous change for the pharmaceutical sector, while passing rebates onto consumers at the point of sale or reforms to the system would be less disruptive